Search

Your search keyword '"MacDougall, Kira"' showing total 33 results
Start Over Author "MacDougall, Kira"
33 results on '"MacDougall, Kira"'

4. The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study

Author

MacDougall, Kira, Niazi, Muhammad Rafay Khan, Hosry, Jeff, Homsy, Sylvester, and Bershadskiy, Alexander

Subjects
Oncology, Experimental, Lung cancer, Small cell -- Care and treatment, Immunotherapy, B cells, Clinical trials, Lung cancer, Non-small cell -- Care and treatment, Cancer -- Research, Biological markers, Health
Abstract

INTRODUCTION: Systemic inflammation has long been associated with poor outcomes in many types of solid tumors. Peripheral blood biomarkers, such as absolute lymphocyte count (ALC) and the ratio of absolute neutrophil count to absolute lymphocyte count (ANC/ALC), have been shown to be immune-inflammatory parameters highlighting an individual's immune status. The prognostic role of ALC and ANC/ALC on overall survival (OS) was examined in patients with advanced non-small cell lung carcinoma (NSCLC) receiving pembrolizumab. Of a total of 239 patients, 52% were male, with a median age of 67 years (interquartile range [IQR], 59-73). Most patients had a diagnosis of adenocarcinoma (76%), with stage IV disease (82%). PD-L1 expression was >50% in 44% of the patients. The median time on treatment with pembrolizumab was 5.8 months (IQR, 2.9-12.7). An ANC/ALC 1.4 deciliter (dL) trended toward improved OS compared with ALC An ANC/ALC KEYWORDS: pembrolizumab; non-small cell lung cancer; absolute lymphocyte count; absolute neutrophil count to absolute lymphocyte count ratio; immunotherapy; peripheral blood counts; anti-PD-1, Introduction Lung cancer is the most common cause of cancer-related deaths, both in the United States and internationally. (1,2) Non-small cell lung cancer (NSCLC) accounts for approximately 80% to 85% [...]

Published
2022

6. Thrombotic Microangiopathy After Hematopoietic Stem Cell and Solid Organ Transplantation: A Review for Intensive Care Physicians.

Author

Nusrat, Sanober, Davis, Hugh, MacDougall, Kira, George, James N., Nakamura, Ryotaro, and Borogovac, Azra

Subjects
HEMATOPOIETIC stem cells, INTENSIVE care units, PRIMARY health care, THROMBOTIC microangiopathies, RITUXIMAB, TRANSPLANTATION of organs, tissues, etc.
Abstract

Intensive care physicians may assume the primary care of patients with transplant-associated thrombotic microangiopathy (TA-TMA), an uncommon but potentially critical complication of hematopoietic stem cell transplants (HSCTs) and solid organ transplants. TA-TMA can have a dramatic presentation with multiple organ dysfunction syndrome (MODS) associated with high morbidity and mortality. The typical presenting clinical features are hemolytic anemia, thrombocytopenia, refractory hypertension, proteinuria and worsening renal failure. Intestinal involvement, with abdominal pain, nausea and vomiting, gastrointestinal bleeding, and ascites are also common. Cardiopulmonary involvement may develop from various causes including pulmonary arteriolar hypertension, pleural and pericardial effusions, and diffuse alveolar hemorrhage. Due to other often concurrent complications after HSCT, early diagnosis and effective management of TA-TMA may be challenging. Close collaboration between ICU and transplant physicians, along with other relevant specialists, is needed to best manage these patients. There are currently no approved therapies for the treatment of TA-TMA. Plasma exchange and rituximab are not recommended unless circulating factor H (CFH) antibodies or thrombotic thrombocytopenic purpura (TTP; ADAMTS activity < 10%) are diagnosed or highly suspected. The role of the complement pathway activation in the pathophysiology of TA-TMA has led to the successful use of targeted complement inhibitors, such as eculizumab. However, the relatively larger studies using eculizumab have been mostly conducted in the pediatric population with limited data on the adult population. This review is focused on the role of intensive care physicians to emphasize the clinical approach to patients with suspected TA-TMA and to discuss diagnosis and treatment strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes

Author

Wagner, Charlotte B., primary, Boucher, Ken, additional, Nedved, Adrienne, additional, Micallef, Ivana N, additional, Desai, Sanjal, additional, Hatic, Haris, additional, Goyal, Gaurav, additional, Zacholski, Erin, additional, Fegley, Amanda, additional, Sigmund, Audrey M., additional, Bond, David A., additional, Samuels, Courtney, additional, Kamdar, Manali K., additional, Ba Aqeel, Sheeba, additional, Torka, Pallawi, additional, MacDougall, Kira, additional, Borogovac, Azra, additional, Rajeeve, Sridevi, additional, Sundaram, Suchitra, additional, Fedak, Kalub, additional, Modi, Dipenkumar, additional, Travers, Elizabeth, additional, Ayyappan, Sabarish, additional, Chilakamarri, Nitin, additional, Brem, Elizabeth A., additional, Ermann, Daniel A., additional, Fitzgerald, Lindsey A., additional, Hu, Boyu, additional, Stephens, Deborah M., additional, and Shah, Harsh, additional

Published
2023
Full Text
View/download PDF

10. Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Author

Wagner, Charlotte B, primary, Ermann, Daniel A., additional, Boucher, Ken, additional, Nedved, Adrienne N., additional, Micallef, Ivana N., additional, Desai, Sanjal H, additional, Hatic, Haris, additional, Goyal, Gaurav, additional, Zacholski, Erin, additional, Fegley, Amanda, additional, Sigmund, Audrey M., additional, Bond, David A., additional, Samuels, Courtney, additional, Kamdar, Manali K., additional, Ba Aqeel, Sheeba, additional, Torka, Pallawi, additional, MacDougall, Kira, additional, Borogovac, Azra, additional, Rajeeve, Sridevi, additional, Sundaram, Suchitra, additional, Fedak, Kalub, additional, Modi, Dipenkumar, additional, Travers, Elizabeth, additional, Ayyappan, Sabarish, additional, Chilakamarri, Nitin, additional, Brem, Elizabeth A, additional, Stephens, Deborah M., additional, Hu, Boyu, additional, Fitzgerald, Lindsey A., additional, and Shah, Harsh, additional

Published
2022
Full Text
View/download PDF

11. Novel Home-Based Transfusion Model of Palliative Care in Malignant Hematology

Author

Saleem, Rabia, primary, MacDougall, Kira, additional, Hassan, Ayesha, additional, Siddiqui, Maria, additional, Khawandanah, Mohamad O., additional, Ikeguchi, Alexandra, additional, Asch, Adam S., additional, Ibrahimi, Sami, additional, Selby, George B., additional, Neelakantan, Deepika, additional, Ledford, Barbara, additional, Le, Tuan N, additional, Vesely, Sara K., additional, Day, Silas A, additional, Madison, Stefani D, additional, Struck, Bryan, additional, Armitage, John, additional, Nipp, Ryann, additional, Minor, Sarah, additional, Yuen, Carrie, additional, and Holter-Chakrabarty, Jennifer, additional

Published
2022
Full Text
View/download PDF

12. P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma

Author

Shah, Harsh, primary, Vardell, Victoria, additional, Zacholski, Erin, additional, Fegley, Amanda, additional, Fedak, Kalub, additional, Sundaram, Suchitra, additional, Rajeeve, Sridevi, additional, Goyal, Gaurav, additional, Hatic, Haris, additional, Torka, Pallawi, additional, Ba Aqeel, Sheeba, additional, Borogovac, Azra, additional, Macdougall, Kira, additional, Kothari, Shalin, additional, Kress, Anna, additional, Modi, Dipenkumar, additional, Travers, Elizabeth, additional, Chilakamarri, Nitin, additional, Brem, Elizabeth, additional, Stephens, Deborah M., additional, Hu, Boyu, additional, Fitzgerlad, Lindsey, additional, Wagner, Charlotte, additional, and Ermann, Daniel, additional

Published
2022
Full Text
View/download PDF

33. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes.

Author

Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, and Shah H

Subjects
Humans, Brentuximab Vedotin, Retrospective Studies, Neoplasm Recurrence, Local drug therapy, Stem Cell Transplantation, Chronic Disease, Treatment Outcome, Hodgkin Disease drug therapy, Hodgkin Disease pathology, Immunoconjugates adverse effects
Abstract

Sixteen cycles of Brentuximab vedotin (BV) after autologous stem cell transplant (ASCT) in high-risk relapsed/refractory classical Hodgkin lymphoma demonstrated an improved 2-year progression-free survival (PFS) over placebo. However, most patients are unable to complete all 16 cycles at full dose due to toxicity. This retrospective, multicenter study investigated the effect of cumulative maintenance BV dose on 2-year PFS. Data were collected from patients who received at least one cycle of BV maintenance after ASCT with one of the following high-risk features: primary refractory disease (PRD), extra-nodal disease (END), or relapse <12 months (RL<12) from the end of frontline therapy. Cohort 1 had patients with >75% of the planned total cumulative dose, cohort 2 with 51-75% of dose, and cohort 3 with ≤50% of dose. The primary outcome was 2-year PFS. A total of 118 patients were included. Fifty percent had PRD, 29% had RL<12, and 39% had END. Forty-four percent of patients had prior exposure to BV and 65% were in complete remission before ASCT. Only 14% of patients received the full planned BV dose. Sixty-one percent of patients discontinued maintenance early and majority of those (72%) were due to toxicity. The 2-year PFS for the entire population was 80.7%. The 2-year PFS was 89.2% for cohort 1 (n=39), 86.2% for cohort 2 (n=33), and 77.9% for cohort 3 (n=46) (P=0.70). These data are reassuring for patients who require dose reductions or discontinuation to manage toxicity.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results